

# Accounting for cross-immunity can improve forecast accuracy during influenza epidemics

Rahil Sachak-Patwa<sup>a\*</sup>, Helen M Byrne<sup>a</sup>, Robin N Thompson<sup>a,b</sup>

<sup>a</sup> Mathematical Institute, University of Oxford, Andrew Wiles Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK

<sup>b</sup> Christ Church, University of Oxford, St Aldates, Oxford, OX1 1DP, UK

\* Correspondence to: [rahil.sachak-patwa@maths.ox.ac.uk](mailto:rahil.sachak-patwa@maths.ox.ac.uk)

July 2, 2020

## Abstract

Previous exposure to influenza viruses confers partial cross-immunity against future infections with related strains. However, this is not always accounted for explicitly in mathematical models used for forecasting during influenza outbreaks. We show that, if an influenza outbreak is due to a strain that is similar to one that has emerged previously, then accounting for cross-immunity explicitly can improve the accuracy of real-time forecasts. To do this, we consider two infectious disease outbreak forecasting models. In the first (the “1-group model”), all individuals are assumed to be identical and partial cross-immunity is not accounted for. In the second (the “2-group model”), individuals who have previously been infected by a related strain are assumed to be less likely to experience severe disease, and therefore recover more quickly than immunologically naive individuals. We fit both models to case notification data from Japan during the 2009 H1N1 influenza pandemic, and then generate synthetic data for a future outbreak by assuming that the 2-group model represents the epidemiology of influenza infections more accurately. We use the 1-group model (as well as the 2-group model for comparison) to generate forecasts that would be obtained in real-time as the future outbreak is ongoing, using parameter values estimated from the 2009 epidemic as informative priors, motivated by the fact that without using prior information from 2009, the forecasts are highly uncertain. In the scenario that we consider, the 1-group model only produces accurate outbreak forecasts once the peak of the epidemic has passed, even when the values of important epidemiological parameters such as the lengths of the mean incubation and infectious periods are known exactly. As a result, it is necessary to use the more epidemiologically realistic 2-group model to generate accurate forecasts. Accounting for partial cross-immunity driven by exposures in previous outbreaks explicitly is expected to improve the accuracy of epidemiological modelling forecasts during influenza outbreaks.

## Keywords

Mathematical modelling; Influenza forecasting; Real-time forecasting; Cross-immunity; 2009 H1N1 pandemic

## 1 Introduction

Three major influenza pandemics have occurred in the 20th century, in 1918, 1957, and 1968 (Kilbourne, 2006). Each pandemic resulted in over a million deaths, with the death toll of the 1918 Spanish Flu pandemic estimated to be 50 million people (Johnson and Mueller, 2002). In 2009, a new strain of the H1N1 virus emerged, due to a reassortment of two swine viruses, triggering the first influenza pandemic of the 21st century (Trifonov et al., 2009; Christman et al., 2011). The virus is believed to have originated in Mexico in April 2009, and then spread rapidly across the globe, reaching 43 countries by May that year (Fraser et al., 2009; Trifonov et al., 2009). The case fatality rate due to the virus was lower than that of previous global pandemics in the 20th century (Kamigaki

40 and Oshitani, 2009). However the scale of the pandemic, with estimates that 11-21% of the global population  
41 contracted the virus, significantly burdened healthcare systems (Kelly et al., 2011).

42 Influenza A viruses mutate over time; antigenic drift produces closely related strains, while antigenic shift  
43 causes major changes in the virus (Bouvier and Palese, 2008; Kim et al., 2018). Due to the random nature of  
44 the evolution of influenza viruses, it is not currently possible to predict when future pandemics will occur, and  
45 which strains will cause these pandemics (Neumann and Kawaoka, 2019). However, mathematical models have  
46 been used extensively for forecasting and informing public health measures when influenza outbreaks are ongoing  
47 (Ferguson et al., 2006; Hall et al., 2007; Nishiura, 2011; Ohkusa et al., 2011; Tizzoni et al., 2012; Biggerstaff  
48 et al., 2016; Thompson and Brooks-Pollock, 2019). Similarly, mathematical models are currently being used to  
49 predict the course of the ongoing COVID-19 pandemic (Ferguson et al., 2020; Kucharski et al., 2020; Prem et al.,  
50 2020; Thompson, 2020).

51 The most basic infectious disease outbreak models assume that individuals are epidemiologically identical  
52 (Chowell et al., 2006; Bettencourt and Ribeiro, 2008). More complex models account for differences between  
53 individuals. For example, in many studies that aim to determine optimal vaccination strategies, populations  
54 are split into low-risk and high-risk groups (Gani et al., 2005; Dushoff et al., 2007), and spatial heterogeneity  
55 can be incorporated by partitioning individuals according to their location (Longini et al., 2004; Ohkusa et al.,  
56 2009). Commonly, due to different rates of contact between individuals of different ages, as well as varying case  
57 fatality rates between age groups, age-structured models are used (Chowell et al., 2009; Medlock and Galvani,  
58 2009; Glasser et al., 2010; Klepac et al., 2018).

59 Other types of heterogeneity are also likely to play an important role in the dynamics of influenza outbreaks.  
60 There is evidence that previous exposure to an influenza virus confers partial immunity to the same or similar  
61 strains, and that this protection is lifelong (Gostic et al., 2016, 2019). This partial cross-immunity may explain  
62 why there has not been a global influenza pandemic as severe as the 1918 pandemic in the last century (Thompson  
63 et al., 2019). It has been shown that a significant proportion of elderly individuals carried pre-existing immunity  
64 to the 2009 H1N1 virus (Hancock et al., 2009; Xing and Cardona, 2009; Bandaranayake et al., 2010; Hardelid  
65 et al., 2010; Gostic et al., 2019). This may be due to the similarities between the 2009 H1N1 virus and the 1918  
66 Spanish Flu virus, as descendants of the 1918 Spanish Flu virus continued to circulate until the 1957 pandemic  
67 (Xu et al., 2010). The consequences of pre-existing immunity can be seen in the age distribution of infected  
68 individuals in Japan in the 2009 pandemic, where only a small proportion of the individuals who sought medical  
69 attention were elderly (Mizumoto et al., 2013). As well as the heterogeneity between hosts in infection risk and  
70 age mentioned previously, models in which populations are structured according to whether or not individuals  
71 carry pre-existing immunity can also be formulated (Andreasen et al., 1997; Martcheva and Pilyugin, 2006; Reluga  
72 et al., 2008; Thompson et al., 2019).

73 In this paper, our attention is directed towards how partial cross-immunity affects the predictability of out-  
74 breaks. We use mathematical models to investigate whether or not it is necessary to account for partially immune  
75 individuals in the population when forecasting the dynamics of future influenza epidemics. We consider two epi-  
76 demiological models. In the first, partial cross-immunity is ignored (the “1-group model”). In the second, more  
77 epidemiologically realistic model (the “2-group model”), individuals with and without partial cross-immunity are  
78 accounted for explicitly.

79 First, we estimate values of parameters of each model (specifically, the transmission rate and the effective  
80 population size) using data from the 2009 H1N1 influenza epidemic in Japan. We then consider a synthetic future  
81 influenza outbreak of a related strain, simulated using the more epidemiologically realistic 2-group model. We  
82 explore whether or not accurate forecasts of the epidemic can be obtained in real-time. If uninformative priors  
83 are used and parameters are estimated in real-time, even the more realistic 2-group model is unable to generate  
84 accurate forecasts of the remainder of the epidemic before the peak occurs. This motivates us to incorporate  
85 information from the 2009 epidemic to set informative priors. We show that forecasts made using the 1-group  
86 model in advance or right at the start of a future epidemic are inaccurate because the model does not account  
87 for the changing number of partially immune individuals over time. We then use both information from the

2009 epidemic and data obtained as the future outbreak is ongoing to make real-time forecasts. Early in the outbreak, only the 2-group model can provide accurate forecasts of the remainder of the epidemic. For that reason, cross-immunity should be included in epidemiological forecasting models whenever an influenza outbreak is related to a strain that has previously caused a major epidemic.

## 2 Methods

### 2.1 Data

Our analysis was based on data from the 2009 H1N1 influenza epidemic in Japan comprising the estimated numbers of weekly cases seeking medical attention in that country. These data were based on data from 4800 randomly sampled sentinel hospitals, extrapolated to the total number of medical facilities in Japan (Nishiura, 2011). The data were acquired from Figure 1 of the analysis by Nishiura (2011) using the data extraction tool <https://automeris.io/WebPlotDigitizer/> and the extracted data are available in Supplementary Data S1. The data represent incident cases of patients who sought medical attention and met one of the following criteria: (i) acute course of illness, (ii) fever higher than  $38^{\circ}\text{C}$ , (iii) cough, sputum or breathlessness (symptoms of upper respiratory infection), (iv) general fatigue, and (v) positive laboratory diagnosis.

It was estimated that 23.5% of the Japanese population was infected during the epidemic, and that 16.1% was infected and sought medical attention (Mizumoto et al., 2013). Therefore  $(23.5 - 16.1)/23.5 = 31.5\%$  of infected individuals did not seek medical attention. We assume that those infected individuals who did not seek medical attention suffered mild symptoms of influenza because they were partially immune to the virus (see discussion). Hence, extrapolating to the rest of the population and assuming that the susceptibility of hosts is unaffected by partial immunity, we assume when fitting the 2-group model that 31.5% of the population were partially immune to the virus and that 68.5% were immunologically naive.

### 2.2 Models

We consider two models characterising influenza outbreaks. In the first (the 1-group model), which is the commonly used SEIR model (Anderson and May, 1991; Mills et al., 2004; Chowell et al., 2006; Chen and Liao, 2008), partial cross-immunity is neglected. In the second (the 2-group model), individuals who have been infected previously by a related strain are assumed to recover from infection more quickly than individuals who are immunologically naive. Schematics of both models are shown in Figure 1.




Figure 1: Schematics of the 1-group and 2-group models. In both cases, the population is compartmentalised into susceptible  $S$ , exposed (infected but not yet infectious)  $E$ , infected  $I$ , and recovered  $R$  classes. The 2-group model distinguishes between partially immune and immunologically naive individuals, and assumes that only infected naive individuals are recorded in case notification data (with perfect reporting). The 1-group model does not distinguish between partially immune and immunologically naive individuals, and assumes that all infected individuals are recorded in case data (again with perfect reporting).

## 115 2.2.1 1-Group Model

The 1-group SEIR model is described by the following differential equations, in which individuals are either (S)usceptible and available for infection, (E)xposed (i.e. infected but not yet infectious or symptomatic), (I)nfectious or, (R)emoved:

$$\frac{dS}{dt} = -\frac{\beta}{N}SI, \quad (1)$$

$$\frac{dE}{dt} = \frac{\beta}{N}SI - \kappa E, \quad (2)$$

$$\frac{dI}{dt} = \kappa E - \mu I, \quad (3)$$

$$\frac{dR}{dt} = \mu I. \quad (4)$$

116 In this model, the infection rate is governed by the parameter  $\beta$ , the mean latent period is  $1/\kappa$  weeks and the  
117 mean infectious period is  $1/\mu$  weeks. The basic reproduction number  $R_0$  of the 1-group model is given by

$$R_0 = \frac{\beta}{\mu}. \quad (5)$$

118 Following Cintrón-Arias et al. (2009), the number of recorded cases in week  $j$  (recorded at the end of that  
119 week) where  $j$  is the integer number of weeks since the epidemic began, is given by

$$C(j) = \int_{j-1}^j \kappa E dt. \quad (6)$$

120 The constant value  $S + E + I + R = N$  represents the effective population size. Since pathogens are most likely  
121 to be transmitted locally, individuals in distant locations are not available for infection and so  $N$  is expected to  
122 be smaller than the true population size (Gart, 1968; Pouillot et al., 2008). In Table 1 we list the parameters  
123 that appear in equations (1)-(4) and estimates of their values for the Japanese 2009 H1N1 epidemic (see also  
124 Section 2.3 and 3.1).

## 125 2.2.2 2-Group Model

The 2-group model is an extension of the standard SEIR model in which immunologically naive and partially  
immune individuals are distinguished between. The 2-group model is given by the following system of differential  
equations:

$$\frac{dS_I}{dt} = -\frac{\beta}{N}S_I(I_I + I_N), \quad (7)$$

$$\frac{dE_I}{dt} = \frac{\beta}{N}S_I(I_I + I_N) - \kappa E_I, \quad (8)$$

$$\frac{dI_I}{dt} = \kappa E_I - \mu_I I_I, \quad (9)$$

$$\frac{dR_I}{dt} = \mu_I I_I, \quad (10)$$

$$\frac{dS_N}{dt} = -\frac{\beta}{N}S_N(I_I + I_N), \quad (11)$$

$$\frac{dE_N}{dt} = \frac{\beta}{N}S_N(I_I + I_N) - \kappa E_N, \quad (12)$$

$$\frac{dI_N}{dt} = \kappa E_N - \mu_N I_N, \quad (13)$$

$$\frac{dR_N}{dt} = \mu_N I_N. \quad (14)$$

126 The basic reproduction number  $R_0$  of the 2-group model is given by

$$R_0 = \frac{\beta}{\mu_I} \frac{\Gamma_1}{\Gamma_1 + \Gamma_2} + \frac{\beta}{\mu_N} \frac{\Gamma_2}{\Gamma_1 + \Gamma_2}, \quad (15)$$

127 where  $\Gamma = (\Gamma_1, \Gamma_2)$  is the eigenvector corresponding to the dominant eigenvalue of the matrix

$$J = \begin{pmatrix} \beta\nu - \mu_I & \beta\nu \\ \beta(1 - \nu) & \beta(1 - \nu) - \mu_N \end{pmatrix}. \quad (16)$$

128 It has been shown that immune imprinting with a previous related influenza strain decreased the numbers of  
 129 severe cases of H1N1, H5N1 and H7N9 influenza (Gostic et al., 2016, 2019). We assume that partially immune  
 130 individuals experience less severe disease and therefore typically recover more quickly than immunologically naive  
 131 individuals (i.e.  $1/\mu_I < 1/\mu_N$ ). To isolate this effect alone on the predictability of epidemics, in this model it is  
 132 assumed that partially immune and naive individuals are otherwise identical.

133 We assume that only cases of severe disease (i.e. infected individuals who were previously immunologically  
 134 naive) report infection, so that the number of recorded cases in week  $j$  is given by

$$C(j) = \int_{j-1}^j \kappa E_N dt. \quad (17)$$

135 Since we assume that only immunologically naive individuals report infection, the infectious period of immuno-  
 136 logically naive individuals in the 2-group model is assumed to be identical to the infectious period of individuals  
 137 in the 1-group model (i.e.  $1/\mu_N = 1/\mu$ ).

138 Denoting the fraction of the population that is partially immune by  $\nu$ , we have that  $S_I + E_I + I_I + R_I = \nu N$   
 139 and  $S_N + E_N + I_N + R_N = (1 - \nu)N$ , where  $S_I + E_I + I_I + R_I + S_N + E_N + I_N + R_N = N$  is the total effective  
 140 population size. In Table 1 we list the parameters that appear in equations (7)-(14) and estimates of their values  
 141 for the Japanese 2009 H1N1 epidemic (again see also Section 2.3 and 3.1).

Parameter	Description	Values	Source
$\beta$	Transmission rate	1.644 Weeks <sup>-1</sup>	Estimated from data (Figure 3)
$N$	Effective population size	$3.072 \times 10^7$	Estimated from data (Figure 3)
$1/\kappa$	Latent period	4/7 Weeks	Tuite et al. (2009)
$1/\mu$	Infectious period	1 Week	Tuite et al. (2009)
$C_0$	Initial number of recorded cases	24073	Mizumoto et al. (2013)

(a): 1-group model

Parameter	Description	Values	Source
$\beta$	Transmission rate	1.947 Weeks <sup>-1</sup>	Estimated from data (Figure 3)
$N$	Total effective population size	$4.660 \times 10^7$	Estimated from data (Figure 3)
$\nu$	Partially immune fraction	0.3149	Mizumoto et al. (2013)
$1/\kappa$	Latent period	4/7 Weeks	Tuite et al. (2009)
$1/\mu_I$	Infectious period (partially immune individuals)	3/7 Weeks	Estimate based on (Fielding et al., 2013)
$1/\mu_N$	Infectious period (naive individuals)	1 Week	Tuite et al. (2009)
$C_0$	Initial number of recorded cases	24073	Mizumoto et al. (2013)

(b): 2-group model

Table 1: Descriptions of parameters of the 1-group and 2-group models and estimates of their values for the Japanese 2009 H1N1 epidemic.

### 142 2.3 Parameter Estimation and Forecasting

143 When fitting the models to each dataset in this study, the transmission rate parameter,  $\beta$ , and effective popula-  
 144 tion size,  $N$ , are estimated using Markov chain Monte Carlo (MCMC) with the Metropolis-Hastings algorithm  
 145 (Hastings, 1970). All other parameters are assumed to be known. A likelihood function is used where it is  
 146 assumed that the differences between the data and model forecasts (where the differences are due to noise not

147 accounted for in the models) are normally distributed, and that this noise scales with the square root of the size  
148 of the data (i.e. the number of cases). We estimate this noise scaling parameter  $\sigma$  in the likelihood function  
149 (which we then fix throughout this study), by first fitting each model to data from the 2009 Japan epidemic  
150 using a least squares approach (Cintrón-Arias et al., 2009). An analysis of the residuals (the difference between  
151 the model values and data) is given in Supplementary Information Section S.1, justifying the square root noise  
152 scaling assumption. In each MCMC simulation, we perform  $2 \times 10^5$  sampling iterations, discarding the first  $10^4$   
153 iterations as the ‘burn-in’ period and record every 100 iterations thereafter to reduce autocorrelation. Further  
154 details are given in Supplementary Information Section S.2.

155 When making forecasts in real-time after  $t = m$  weeks of the epidemic has passed, we calibrate our model  
156 forecasts with the observed data for weeks  $0, 1, \dots, m$  of the epidemic, estimating model parameters using the  
157 method just described. To generate forecasts, we re-calibrate our models to the last observed number of recorded  
158 cases at week  $m$ , estimating the initial conditions from the entirety of the epidemic so far, up to and including  
159 week  $m$  (for details, see Supplementary Information Section S.3).

## 160 **2.4 Modelling the Size of the Partially Immune Population between Epidemics**

161 For the 2-group model, we assume that all immunologically naive individuals infected during an earlier epidemic  
162 acquire partial immunity to related strains of the virus (and that partially immune individuals who were infected  
163 remain partially immune to related strains). We assume further that once an individual acquires partial immunity,  
164 they remain partially immune throughout their lifetime (Gostic et al., 2016, 2019). Using these assumptions, we  
165 can model the partially immune fraction of the population over the years between the end of a first epidemic  
166 and the start of a future epidemic of a related strain of influenza. We assume the next epidemic infects the same  
167 effective population as the first one (in 2009). This immune fraction of the population will decay due to births  
168 and deaths, which we now consider because the timespan between major influenza epidemics (which are often  
169 part of global pandemics) is typically many years (Kilbourne, 2006). Further details are given in Supplementary  
170 Information Section S.4. We seed the future epidemics by assuming there are 10,000 recorded cases in the first  
171 week from which we generate forecasts (three orders of magnitude smaller than the effective population sizes  
172 used in our models). When using the 2-group model to forecast future epidemics, we assume we know the partial  
173 immune fraction of the population exactly.

## 174 **2.5 Approaches to Forecasting a Future Epidemic**

175 In Figure 1 we have presented two mathematical models which can be used to forecast influenza epidemics. As  
176 well as determining which model to use, we shall investigate three forecasting approaches (see Figure 2 for a  
177 schematic of these approaches).




Figure 2: Schematic of the modelling approaches to forecast the dynamics of a future epidemic. The shaded regions indicate the 95% confidence intervals of epidemic curve trajectories and forecasts. (a) Strategy 1: Forecast in real-time, using data from the ongoing epidemic and assuming no prior information about the fitting parameters. Cyan and green forecasts calibrated using data up to week 10 and 20 of the epidemic respectively. (b)-(c) Strategy 2: Forecast in advance of a future epidemic using prior parameter distributions estimated from fitting the model to data from a previous epidemic (priors shown in panel inside (b)). (d)-(e) Strategy 3: Forecast in real-time, using data from the ongoing epidemic as well as prior parameter distributions estimated from fitting the model to data from a previous epidemic.

### 178 3 Results

#### 179 3.1 Fitting Models to the 2009 H1N1 Influenza Epidemic in Japan

180 We fit the 1-group and 2-group models to data from the 2009 H1N1 influenza epidemic (Figure 3 (a), (b)).  
 181 The shaded regions represent the 95% confidence intervals of epidemic curve trajectories based on the posterior  
 182 distributions of fitting parameters  $\beta$  and  $N$ . Since the 1-group model does not account for infected but unrecorded  
 183 individuals, the estimated parameters for the model represent a lower effective population size  $N$  and basic  
 184 reproduction number  $R_0$  than the analogous estimates for the 2-group model (Figure 3 (c), (d)). The mean

185 estimated values of  $R_0$  of the 1- and 2-group models are 1.644 (95%CI [1.644, 1.653]) and 1.720 (95%CI [1.704,  
 186 1.736]) respectively, comparable with the interquartile range of 1.30 to 1.70 based on fifty-seven studies of the  
 187 2009 H1N1 pandemic strain (Biggerstaff et al., 2014). The values for the estimated parameters and confidence  
 188 intervals are stated in Table 2. The numbers of recorded, unrecorded, and combined total weekly cases estimated  
 189 using the 2-group model are shown in Supplementary Information Section S.5.

190 We use the mean estimated transmission rate and effective population size from the 2-group model to generate  
 191 synthetic data for future epidemics. We assume that, if the simulated epidemic takes place further in future,  
 192 then the immune fraction of the population is lower due to deaths of partially immune hosts and births of  
 193 immunologically naive hosts (see Supplementary Information Section S.4).




Figure 3: (a)-(b): The 1-group and 2-group models fitted to data of the number of new recorded cases each week from the 2009 H1N1 influenza epidemic in Japan, using the transmission rate  $\beta$  and effective population size  $N$  as fitting parameters. Solid lines and shaded regions indicate the mean and 95% confidence intervals of epidemic curve trajectories based on the posterior distributions of the parameters. (c)-(d): Scatter plots of posterior distributions of  $R_0$  (directly proportional to  $\beta$ ) and  $N$ . Red dots represent the mean estimates of the parameters. Estimated parameters along with their confidence intervals are given in Table 2.

Parameter	Mean	95% CI
$\beta$	1.644	[1.627, 1.662]
$N$	$3.072 \times 10^7$	$[2.905, 3.246] \times 10^7$

(a): 1-group model

Parameter	Mean	95% CI
$\beta$	1.947	[1.927, 1.966]
$N$	$4.660 \times 10^7$	$[4.388, 4.938] \times 10^7$

(b): 2-group model

Table 2: Mean values and confidence intervals of the fitting parameter posterior distributions, of the 1-group and 2-group models, fitted to data from the 2009 H1N1 influenza epidemic in Japan.



## 194 **3.2 Forecasting an Epidemic in Real-Time without Prior Information**

195 If a major influenza epidemic were to occur, we would want to make real-time forecasts of its dynamics using  
196 live data of the number of cases each week to update predictions. We consider the case of a future epidemic  
197 occurring 25 years after the 2009 outbreak. We make forecasts using the 1- and 2-group models, at 10, 20, and  
198 30 weeks after the first recorded cases. The results presented in Figure 4 show how the model forecasts change  
199 as we update them. The uncertainty in the forecasts of both models is large when they are made at weeks  
200 10 or 20. By contrast, if forecasts are made at week 30, then they accurately describe the remainder of the  
201 epidemic. We remark that at week 30, the peak of the epidemic has already passed and so accurate forecasting  
202 is less practically useful. We conclude that it is difficult to forecast the dynamics of an epidemic in real-time  
203 without prior information about the transmission rate and effective population size. This result motivates us  
204 to use information from previous epidemics when forecasting the dynamics of a future one; we investigate this  
205 further below.




Figure 4: Forecast Strategy 1: real-time forecasts obtained from the 1-group and 2-group models of a future epidemic occurring 25 years after the 2009 epidemic, calibrated by fitting the model parameters  $\beta$  and  $N$  to data of new cases, using uninformative uniform priors. Forecasts are made at weeks 10, 20, and 30 of the epidemic, using the observed data to estimate model parameters. Vertical lines separate the calibration and forecasting periods. Dashed lines indicate the mean of the epidemic curve trajectories in the model calibration period. Solid lines and shaded regions indicate the mean and 95% confidence intervals of the forecasts, based on the posterior distributions of the parameters. The synthetic data were generated using the mean parameters of the 2-group model fitted to data from the 2009 epidemic. Uniform priors  $N \in [10 \times 10^6, 128 \times 10^6]$  and  $\beta \in [1, 3]$  are used.

### 206 3.3 Forecasting Epidemics in Advance

207 Using estimates of  $\beta$  and  $N$ , calculated by fitting the 1- and 2-group models to the 2009 epidemic, we can prescribe  
 208 these parameters to follow informative gamma distributions to more accurately forecast future epidemics (values  
 209 given in Supplementary Information Section S.6). We use our models to generate forecasts of the dynamics of  
 210 future major influenza epidemics in Japan arising from a related strain and occurring 25, 50, or 75 years after the  
 211 2009 epidemic (with no major epidemics occurring in each intervening period). The forecasts in Figure 5 show  
 212 that if the 1-group model is used where partial cross-immunity is neglected, the dynamics of a future epidemic  
 213 are identical to those of the 2009 epidemic, regardless of when it occurs. By contrast, for the 2-group model, a

214 large proportion of the population would be partially immune after the 2009 epidemic, resulting in a lower basic  
215 reproduction number. Consequently, if a related strain were to emerge 25 years later, the epidemic would be  
216 smaller than in 2009 (Figure 5 (a)-(b)). If the next major epidemic occurred 75 years later, a large proportion  
217 of the population would be immunologically naive to a related strain of the 2009 virus (because of population  
218 turnover due to births and deaths), resulting in a greater basic reproduction number. Hence, if all other factors  
219 were similar to those in 2009, the future epidemic would be larger than in 2009 (Figure 5 (e)-(f)).

220 Assuming the 2-group model more accurately reflects the underlying epidemiology of the system, we conclude  
221 that the 1-group model forecasts may differ markedly from the dynamics of the next epidemic of a related strain.  
222 Forecasts using larger and smaller variances of the distributions of  $\beta$  and  $N$  are presented in Supplementary  
223 Information Section S.7. The partially immune fraction, basic reproduction number, total number of recorded  
224 cases, duration, and size and timing of the peak of the epidemic forecasted using the 2-group model, as the time  
225 between epidemics increases, are shown in Supplementary Information Section S.8. As seen in Figure 5, the  
226 further into the future the next epidemic of a related strain occurs then, all else being equal, the greater the total  
227 and peak number of cases and the shorter the duration of the epidemic.




Figure 5: Forecasts Strategy 2: forecasts obtained from the 1-group and 2-group models of epidemics in advance, occurring 25, 50, and 75 years after the 2009 epidemic. Forecasts generated by assuming the parameters  $\beta$  and  $N$  follow a gamma distribution, set by fitting the models to data from the previous 2009 epidemic (details in Supplementary Information Section S.6). Solid lines and shaded regions indicate the mean and 95% confidence intervals of the forecasts. The synthetic data were generated using the mean parameters of the 2-group model fitted to data from the 2009 epidemic.

### 228 3.4 Forecasting an Epidemic in Real-Time with Prior Information

229 We showed above that real-time forecasts of an influenza epidemic, without informative priors for the fitting  
 230 parameters, were typically very uncertain (e.g. Figure 4 (a)-(b)). We therefore now consider using priors to  
 231 inform the fitted parameter values, so that real-time forecasts are based on both historical data (from the 2009  
 232 epidemic) and live data from the ongoing outbreak. Gamma distributed priors were set for  $\beta$  and  $N$ , with mean  
 233 values based on parameter estimates from the 2009 epidemic.

234 As before, we consider a scenario in which an epidemic occurs 25 years after the 2009 epidemic. In turn,  
 235 predictions were made 0, 10, 20, and 30 weeks after the start of the ongoing epidemic (Figure 6 (a)-(b), (c)-(e),  
 236 (f)-(h) and (i)-(k), respectively).

237 We considered different widths of priors used to inform the epidemic forecasts (Figure 6 and figures in

238 Supplementary Information Section S.9). Under the baseline variance considered, when the 1-group model was  
239 used, there was sometimes a discrepancy between the calibrated model trajectory and the observed epidemic  
240 data (e.g. left part of Figure 6 (f)). For that reason, we also show epidemic forecasts obtained using a wider prior  
241 (Figure 6 (d), (g) and (j)), so that the model fits the observed data more accurately. When the 1-group model  
242 is used, the forecast is either inaccurate (when a prior with low variance is used; e.g. Figure 6 (c)) or imprecise  
243 (when a prior with higher variance is used; e.g. Figure 6 (d)). In either case, our main conclusion is unchanged:  
244 predictions are improved when the more epidemiologically realistic 2-group model is used.




Figure 6: Forecast Strategy 3: forecasts obtained from the 1-group and 2-group models of a future epidemic occurring 25 years after the 2009 epidemic, in advance (at week 0) of the epidemic (a)-(b), and calibrated by fitting the models to data of new cases during the outbreak (c)-(k). Gamma distributed priors are prescribed on the fitting parameters  $\beta$  and  $N$ , set by fitting the models to data from the previous 2009 epidemic (details in Supplementary Information Section S.6). Forecasts are made at weeks 10, 20, and 30 of the epidemic, using the observed data to estimate model parameters. Vertical lines separate the calibration and forecasting periods. Dashed lines indicate the mean of the epidemic curve trajectories in the model calibration period. Solid lines and shaded regions indicate the mean and 95% confidence intervals of the forecasts, based on the posterior distributions of the parameters. The synthetic data were generated using the mean parameters of the 2-group model fitted to data from the 2009 epidemic.

## 4 Discussion

Influenza epidemics, particularly pandemics, cause a significant burden on healthcare systems throughout the world (Monto, 2004). It is widely known that exposure to an influenza virus confers partial immunity to related strains (Gostic et al., 2016, 2019), and yet, partial immunity is often neglected in influenza forecasting models (Baguelin et al., 2013; Rajaram et al., 2017). In this study we have investigated whether or not it is necessary to account for partial cross-immunity when forecasting influenza epidemics and, moreover, whether data from previous epidemics can improve forecasts.

We have considered two different mathematical models which describe the spread of influenza, a 2-group model which differentiates between immunologically naive and partially immune individuals, and a 1-group model which does not. We parameterise each model using data of the estimated number of cases of infected individuals seeking medial attention per week during the 2009 H1N1 epidemic in Japan (Nishiura, 2011). When forecasting the dynamics of an epidemic of a related strain 25 years after the 2009 outbreak when there is no prior knowledge of the transmission rate and effective population size, we show that neither model predicts the dynamics of the epidemic in real-time early on during the outbreak with any certainty. Similar uncertainty was also seen when real-time forecasts were generated from an ordinary differential equation model with data from the 1918, 1957, and 1968 influenza pandemics (Hall et al., 2007).

We forecast the dynamics of future epidemics occurring at a range of time intervals after the 2009 epidemic. Immediately after the 2009 epidemic, a large fraction of the population will be partially immune to strains that are related to the 2009 H1N1 virus. This fraction reduces as the time since the 2009 epidemic increases, as individuals (a large proportion of whom carry partial immunity) die and immunologically naive individuals are born. Consequently, the size of a future epidemic of a related strain increases the further into the future at which it occurs. If we neglect partial cross-immunity by using the 1-group model, we predict the same outbreak dynamics as in 2009, regardless of when it occurs. This is because changing numbers of partially immune individuals are not accounted for. This would either result in an overestimation of the size of a future epidemic, if the partially immune fraction was greater than the baseline partial immunity in 2009 (i.e. if the future outbreak occurred soon after 2009), or an underestimation, if it was less (i.e. if the future outbreak occurred long after 2009).

Finally, we considered incorporating knowledge of parameters from the 2009 epidemic, combined with using outbreak data to make real-time forecasts during a future epidemic. When the 1-group model was used to make forecasts, we found that wide priors had to be used to calibrate the model trajectories to the data, especially early on. Although these priors, based on the 2009 epidemic, improved the forecasts compared to when no prior information was used, the forecasts were still uncertain when made before the peak of the epidemic. By contrast, the 2-group was able to make more accurate forecasts as it accounted for the changes in the number of partially immune individuals and, hence, its priors accurately reflected the values of the true underlying parameters of the system. We conclude that to forecast the long-term dynamics of major influenza epidemics, a model that accounts for partial cross-immunity should be used, and data from related previous epidemics taken into account.

We note that there may be instances in which the underlying epidemiology of an outbreak is not well known, or where a complex model cannot be parameterised due to poor surveillance and or lack of data (Gibbons et al., 2014). In such cases, using a simple model akin to the 1-group model used in this study may be the only possible option for making predictions. Although forecasts made by a 1-group model may lack precision, they could still be useful to policy makers during an epidemic. For example, the 1-group model was able to accurately predict the duration of the epidemic when using data from the first 10 weeks of the outbreak, even if it could not predict well the trajectory of the entire epidemic. Such models may also be useful for short-term forecasts (Funk et al., 2019). By constantly updating model predictions using new data, and adjusting parameter assumptions when model calibration trajectories deviate from the data, simple models which do not describe the underlying epidemiology of an epidemic fully may still be informative.

We investigated whether or not it is necessary to include a particular source of heterogeneity (i.e. partial immunity) when forecasting influenza epidemics. In a similar manner, we could extend our models to question

292 whether other sources of heterogeneity should be accounted for. For instance, age-structure could be incorporated  
293 (Nishiura et al., 2010). We could also include spatial heterogeneity, by partitioning the population into distinct  
294 geographical regions (Ohkusa et al., 2009). A significant challenge with this extension would be identifying the  
295 transmission rates between different regions.

296 In the 2-group model considered here, we assumed, as in Reichert et al. (2012), that immunoprotection does  
297 not prevent infection, only its consequences. Different types of partial cross-immunity to related strains of a  
298 virus can be considered. For example, in Thompson et al. (2019) it was assumed that cross-immunity decreases  
299 susceptibility, that is, the probability that an individual becomes infected, an assumption also used in influenza  
300 transmission models (Hill et al., 2019). Future work could consider whether or not the results of this study hold  
301 when different assumptions are made about the precise effects of cross-immunity. In the 2-group model, in order  
302 to study the effects of cross-immunity in as simple a setting as possible, we assumed that infected individuals who  
303 did not seek medical attention were already partially immune to the virus. However, a range of factors (including  
304 age and behaviour) are likely to affect the probability that an individual seeks medical attention. This could  
305 be built into the underlying modelling framework considered here, although additional data would be needed to  
306 parameterise the resulting model. Other additions to the 1- and 2-group models could also be considered. For  
307 example, the wide range of interventions that are implemented during outbreaks could be included in the models  
308 explicitly (Gani et al., 2005; Longini et al., 2005; Backer et al., 2019).

309 Nonetheless, our approach has demonstrated the principle that including partial cross-immunity in forecasting  
310 models during influenza epidemics can lead to more accurate forecasts. Cross-immunity due to previous infection  
311 has been shown to play a major role in the dynamics of influenza epidemics, with clear evidence emerging from  
312 the 1918 Spanish Flu pandemic (Taubenberger and Morens, 2006) and the 2009 H1N1 pandemic (Hancock et al.,  
313 2009). We expect cross-immunity to remain important in future influenza epidemics. Consideration of partial  
314 cross-immunity by epidemiological modellers is therefore of obvious public health importance.

## 315 **Author's Contributions**

316 All authors conceived the study. RS-P conducted the analysis. RNT and HMB supervised the research. All  
317 authors wrote and revised the manuscript. All authors approved the final version of the manuscript.

## 318 **Funding**

319 This publication is based on work supported by the EPSRC Centre For Doctoral Training in Industrially Focused  
320 Mathematical Modelling (EP/L015803/1) in collaboration with Biosensors Beyond Borders Ltd. (RS-P). It was  
321 also funded by Christ Church (Oxford) via a Junior Research Fellowship (RNT).

## 322 **Declaration of Competing Interests**

323 We have no competing interests.

## 324 **Acknowledgements**

325 Thanks to Erin Lafferty and Claude Schmit (Biosensors Beyond Borders Ltd.), and the members of the Wolfson  
326 Centre for Mathematical Biology (University of Oxford) for helpful discussions about the work.



## 327 Supplementary Information

### 328 S.1 Residual Analysis of Models Fitted to the 2009 Epidemic

329 There may be situations in which the assumptions of a model underlying the parameter estimation framework  
330 are violated, for instance, how the amplitude of the noise in the data scales with the number of cases. These  
331 incorrect assumptions may not be immediately apparent when observing the fitted models and data. However,  
332 to look for any systematic deviations between the fitted models and data, we can carry out a residual analysis,  
333 plotting the residuals (the differences between the model values and observed data) against time and the model  
334 values (Cintrón-Arias et al., 2009).

335 In Figure S1 we plot the residuals, as calculated by (S6) of the 1-group and 2-group models with least squares  
336 estimated parameters (see Supplementary Information Section S.2), fitted to data from the 2009 H1N1 influenza  
337 epidemic in Japan, against the model values (number of cases) and time. There are no trends or any discernible  
338 patterns in any panel in Figure S1, which suggests that it is reasonable to assume that the noise in the observed  
339 data of the number of cases scales with the square root of the size of the data.




Figure S1: Residuals of the 1-group and 2-group models fitted to data from the 2009 H1N1 influenza epidemic in Japan, with least squares estimated parameters, calculated using (S6), plotted against the model value and time.

## 340 S.2 Parameter Estimation

341 We use Markov chain Monte Carlo (MCMC) with the Metropolis-Hastings algorithm to estimate model param-  
342 eters (Hastings, 1970). It is assumed that the noise in the observed data scales with the square root of the size  
343 of the data (i.e. the number of cases), hence we use the likelihood function

$$\mathcal{L} = \prod_{j=1}^n \frac{1}{Z} \exp\left(\frac{-(z(t_j; \theta) - y_j)^2}{2z(t_j; \theta_0)\sigma^2}\right), \quad (\text{S1})$$

344 where  $z(t_j, \theta_0)$  are the number of cases given by our model with the parameters  $\theta$ ,  $y_j$  are the observed data, and  
345  $Z$  is a normalisation constant we need not consider.

346 To determine  $\sigma$ , we first fit the 1- and 2-group models to data from the 2009 epidemic in Japan using a least  
347 squares procedure, again assuming that the observed data scales with the square root of the size of the data,  
348 and that the observed data deviates from the model forecasts due to noise which the model does not account for,  
349 such that

$$y_j = z(t_j; \theta) + \epsilon_j z(t_j; \theta)^{1/2} \quad \text{for } j = 1, \dots, n, \quad (\text{S2})$$

350 where  $\epsilon_j$  are assumed to be independent and identically distributed random variables with zero mean  $E[\epsilon_j] = 0$   
351 and finite variance  $\text{var}[\epsilon_j] = \sigma^2$ . We define the cost function

$$J(\theta) = \sum_{j=1}^n \frac{[y_j - z(t_j; \theta)]^2}{z(t_j; \theta)}, \quad (\text{S3})$$

352 The least squares parameter estimates are given by

$$\hat{\theta} = \arg \min_{\theta \in \Theta} J(\theta), \quad (\text{S4})$$

353 where  $\Theta$  is the feasible set of parameter values. We solve the optimisation problem (S4) using MATLAB's  
354 `fminsearch` function.

355 Following Cintr3n-Arias et al. (2009), we estimate the noise scaling parameter  $\sigma^2$  by

$$\sigma^2 \approx \frac{1}{n-p} J(\hat{\theta}), \quad (\text{S5})$$

356 where  $p$  is the number of parameters estimated from the data, and define the residuals by the ratio

$$\text{res}_j = \frac{y_j - z(t_j; \hat{\theta})}{z(t_j; \hat{\theta})^{1/2}}. \quad (\text{S6})$$

357 When fitting the models to data from the 2009 epidemic in Japan, we estimate  $\sigma$  using (S5), calculating  
358  $\sigma = 123.5$  for the 1-group model and  $\sigma = 123.9$  for the 2-group model respectively. Hence, we use the value  
359  $\sigma = 124$  in the likelihood function (S1) throughout this study. A residual analysis of both models with the least  
360 squares estimated parameters is given in Supplementary Information Section S.1, justifying the assumption the  
361 noise in the observed data scales with square root size of the data.

### 362 S.3 Estimation of Initial Conditions

363 The observable data we consider is the number of cases that have been recorded each week,  $C(j)$ . Given that  
 364 we observe  $C(j)$  for  $j = 0, 1, \dots, m$ , we wish to estimate the number of individuals in each compartment of our  
 365 models at week  $j$  as initial conditions to make forward forecasts.

366 When estimating initial conditions from case data from multiple previous week (i.e. when we are part way  
 367 through an epidemic), it is necessary to take data from every week into account, as for instance, an individual  
 368 who was reported as being infected many weeks ago may not have recovered yet. As we estimate initial conditions  
 369 from the observed data rather than model trajectories, we make the assumption that the cases are generated  
 370 uniformly in time (e.g. if there were seven cases reported in one week, we assume that there was one new case  
 371 each day).

Assuming an exponentially distributed infectious period as in our models, and first considering the 1-group model, if  $C(j)$  cases were reported each week for  $j = 0, 1, \dots, m$ , the number of infected individuals  $I$  at week  $m$  is given by

$$I(m) = \sum_{j=0}^m \int_{j-1}^j e^{-\mu(m-t)} C(j) dt \quad (\text{S7})$$

$$= \sum_{j=0}^m \frac{C(j)}{\mu} \left[ e^{-\mu(m-j)} - e^{-\mu(m+1-j)} \right]. \quad (\text{S8})$$

372 Restating (6), we have

$$C(m) = \int_{m-1}^m \kappa E dt. \quad (\text{S9})$$

373 Hence, by assuming a constant  $E$  over the past week, we can make the estimation

$$E(m) = \frac{C(m)}{\kappa}. \quad (\text{S10})$$

374 The number of newly recovered individuals each week is given by the difference between the number of new cases  
 375 and the number of individuals relating to those cases who are still infected. Hence, we estimate the number of  
 376 recovered individuals  $R$  at week  $m$  by

$$R(m) = C(j) \left( 1 - \frac{1}{\mu} \left[ e^{-\mu(m-j)} - e^{-\mu(m+1-j)} \right] \right). \quad (\text{S11})$$

377 As we have assumed a total fixed effective population size  $N$ , the number of susceptibles at week  $m$  is given by

$$S(m) = N - [E(m) + I(m) + R(m)]. \quad (\text{S12})$$

378 We now consider the 2-group model. As it is assumed that only cases of naive individuals becoming infected  
 379 are reported, we estimate the number of infected naive individuals at week  $m$  to be

$$I_N(m) = \sum_{j=0}^m \frac{C(j)}{\mu_N} \left[ e^{-\mu_N(m-j)} - e^{-\mu_N(m+1-j)} \right]. \quad (\text{S13})$$

380 As partially immune and naive individuals are equally likely to be infected, we estimate the number of new  
 381 (unrecorded) cases of infectious partially immune individuals each week to be  $\frac{\nu}{1-\nu} C(j)$ . Hence, we estimate that

$$I_I(m) = \sum_{j=0}^m \frac{\nu}{1-\nu} \frac{C(j)}{\mu_I} \left[ e^{-\mu_I(m-j)} - e^{-\mu_I(m+1-j)} \right]. \quad (\text{S14})$$

The number of exposed, recovered, and susceptible individuals at week  $m$  in each group are estimated by

$$E_N(m) = \frac{C(m)}{\kappa}, \quad (\text{S15})$$

$$E_I(m) = \frac{\nu}{1-\nu} \frac{C(m)}{\kappa}, \quad (\text{S16})$$

$$R_N(m) = \sum_{j=0}^m C(j) \left( 1 - \frac{1}{\mu_N} \left[ e^{-\mu_N(m-j)} - e^{-\mu_N(m+1-j)} \right] \right), \quad (\text{S17})$$

$$R_I(m) = \sum_{j=0}^m \frac{\nu}{1-\nu} C(j) \left( 1 - \frac{1}{\mu_I} \left[ e^{-\mu_I(m-j)} - e^{-\mu_I(m+1-j)} \right] \right), \quad (\text{S18})$$

$$S_N(m) = (1-\nu)N - [E_N(m) + I_N(m) + R_N(m)], \quad (\text{S19})$$

$$S_I(m) = \nu N - [E_I(m) + I_I(m) + R_I(m)]. \quad (\text{S20})$$

## 382 S.4 Modelling the Partially Immune Fraction of the Population

383 We assume that all infected naive individuals in the 2009 H1N1 influenza epidemic in Japan acquired partial  
 384 immunity to the virus and related strains. Hence, we can compute the partially immune fraction of the population  
 385 immediately after the epidemic,  $\nu^*$ , by

$$\nu^* = \nu + \frac{C_T}{N}, \quad (\text{S21})$$

386 where  $\nu$  is the immune fraction before the epidemic,  $C_T$  is the number of total cases recorded in the data, and  
 387  $N$  is the total effective population size. Hence, from the 2-group model fitted to data from the 2009 epidemic in  
 388 Japan as shown in Figure 3, we estimate the partially immune fraction of the population immediately after the  
 389 epidemic to be  $\nu^* = 0.7443$ , using the mean estimated total effective population size,  $N = 4.660 \times 10^7$ .

390 To determine the partially immune fraction when a second epidemic in the future begins, we shall compute  
 391 the fraction as a function of the time since the end of the first epidemic. We shall assume that once an individual  
 392 acquires partial immunity, they remain partially immune for their lifetime.

393 Using population data from Japan in 2009 accessed from National Institute of Population and Social Security  
 394 Research (2020), which we display in Figure S2, we define the number of individuals aged  $a$  by  $b(a)$ , and the  
 395 number of the number of deaths of individuals aged  $a$  by  $d(a)$ . Hence, the probability,  $P(a, n)$ , that an individual  
 396 of age  $a$  survives for  $n$  more years is given by

$$P(a, n) = \prod_{i=0}^{n-1} \left( 1 - \frac{d(a+i)}{b(a+i)} \right), \quad (\text{S22})$$

397 where  $d(a)/b(a)$  is the probability than an individual aged  $a$  dies within one year.

398 The fraction of individuals who have survived for  $n$  years is then given by

$$\frac{1}{M} \sum_{a=0}^{a_m} b(a) P(a, n), \quad (\text{S23})$$

399 where  $M = \sum_{a=0}^{a_m} b(a)$ , and  $a_m$  is the assumed maximum age of an individual, which we take to be 110. Hence  
 400 assuming a constant population size and that all individuals are born immunologically naive, we can calculate  
 401 the immune fraction  $\nu$ ,  $n$  years after the first epidemic to be

$$\nu(n) = \frac{\nu^*}{N} \sum_{a=0}^{\infty} P(a, n), \quad (\text{S24})$$

402 where  $\nu^*$  is the immune fraction immediately after the first epidemic. The result is shown in Figure S6 (a) (see  
 403 Supplementary Information Section S.8). For an epidemic occurring 25 years after 2009 as we consider in this  
 404 study, the partially immune fraction of the population at the start of the epidemic is  $\nu = 0.5129$ .




Figure S2: (a): The age distribution of the population of Japan in 2009. (b): The age distribution of the probability that an individual in Japan dies within on year, based on mortality and population data from 2009. Data accessed from National Institute of Population and Social Security Research (2020)

## 405 S.5 2-Group Model Fitted to the 2009 Epidemic: Total Recorded and Unrecorded 406 Cases

407 We assume that all cases of immunologically naive infected individuals are recorded in the data, and that no cases  
408 relating to partially immune individuals are recorded, due to the assumption that naive individuals suffer more  
409 severe symptoms and are therefore more likely to seek medical attention. In Figure S3 we display the number  
410 of (recorded) infected naive individuals, the number of (unrecorded) infected partially immune individuals, and  
411 their combined total, estimated by the 2-group model fitted to the data from the 2009 epidemic in Japan.




Figure S3: The weekly number of recorded, unrecorded, and total (recorded and unrecorded) cases as estimated by the 2-group model with mean estimated parameters, fitted to data from the 2009 Japanese influenza epidemic.

## 412 S.6 Prior Fitting Parameter Distributions

413 We prescribe prior gamma parameter distributions on  $\beta$  and  $N$  using estimated values from the 2009 epidemic.  
 414 Different variances of these distributions may be considered when making forecasts, values of which are given in  
 415 Table S1.

Figure	Parameter	Mean	Variance	Relative Variance
5, 6 (a), 6(c), 6(f), 6(i)	$\beta$	1.644	$5 \times 10^{-3}$	1
5, 6 (a), 6(c), 6(f), 6(i)	$N$	$3.063 \times 10^7$	$1 \times 10^{13}$	1
6 (d), 6 (g), 6 (j), S4, S7	$\beta$	1.644	$2.5 \times 10^{-2}$	5
6 (d), 6 (g), 6 (j), S4, S7	$N$	$3.063 \times 10^7$	$5 \times 10^{13}$	5
S5, S8	$\beta$	1.644	$1 \times 10^{-3}$	0.2
S5, S8	$N$	$3.063 \times 10^7$	$2 \times 10^{12}$	0.2

(a): 1-group model

Figure	Parameter	Mean	Variance	Relative Variance
5, 6	$\beta$	1.947	$5 \times 10^{-3}$	1
5, 6	$N$	$4.649 \times 10^7$	$1 \times 10^{13}$	1
S4, S7	$\beta$	1.947	$2.5 \times 10^{-2}$	5
S4, S7	$N$	$4.649 \times 10^7$	$5 \times 10^{13}$	5
S5, S8	$\beta$	1.947	$1 \times 10^{-3}$	0.2
S5, S8	$N$	$4.649 \times 10^7$	$2 \times 10^{12}$	0.2

(b): 2-group model

Table S1: Mean and variance of prior gamma distributions of the transmission rate  $\beta$  and effective population size  $N$  used to make forecasts of future epidemics using the 1-group and 2-group models, set by fitting models to data from the 2009 epidemic.

## 416 S.7 Forecasting Epidemics in Advance using Different Prior Parameter Distribu- 417 tions

418 Different variances of the prior parameter distributions of  $\beta$  and  $N$  may be considered by modellers. We show  
419 forecasts of future epidemics made in advance of future outbreaks occurring 25, 50, and 75 years after the 2009  
420 epidemic, if variances five times larger (Figure S4) or five times smaller (Figure S5) of both  $\beta$  and  $N$  are used,  
421 compared to forecasts made in Figure 5.




Figure S4: Forecasts obtained from the 1-group and 2-group models of epidemics occurring 25, 50, and 75 years after the 2009 epidemic as in Figure 5, but with variances of the gamma distributions of  $\beta$  and  $N$  five times larger (details in Supplementary Information Section S.6).






Figure S5: Forecasts obtained from the 1-group and 2-group models of epidemics occurring 25, 50, and 75 years after the 2009 epidemic as in Figure 5, but with variances of the gamma distributions of  $\beta$  and  $N$  five times smaller (details in Supplementary Information S.6).

## 422 S.8 Outbreak Statistics of Future Epidemics

423 In Figure S6 we show how the partially immune fraction, basic reproduction numbers, and various quantities of  
424 interest relating to the dynamics of a future epidemic (estimated using both the 1-group and 2-group models) vary  
425 dependent on when the future epidemic occurs. The partially immune fraction decreases approximately linearly  
426 before tapering to zero as time increases (Figure S6 (a)). This results in an increase in the basic reproduction  
427 number,  $R_0$ , of the 2-group model (Figure S6 (b)).

428 We explore various quantities of interest which would inform policy makers on how best to control the  
429 epidemic: (i) the total number of recorded cases of individuals seeking medical attention, (ii) the duration of the  
430 epidemic, (iii): the maximum weekly number of recorded cases, and (iv): the time at which the maximum weekly  
431 number of recorded cases occurs. Under the assumptions of the 1-group model, these are all forecasted to be  
432 fixed irrespective of when the next epidemic begins, and identical to that of the 2009 epidemic. However, under  
433 the assumptions of the 2-group model, these quantities all vary, which we now describe, as well as motivations  
434 for determining them.

435 The total number of recorded cases of individuals seeking medical attention reflects the number of total medical  
436 resources (e.g. antivirals, hospital beds, staff) required to treat individuals (Figure S6 (c)). This increases in  
437 the 2-group model the further into the future the next epidemic begins, due to the decreasing partially immune  
438 population fraction. It would be useful for public health officials and medical facilities to know the expected  
439 duration of the epidemic so they can plan and allocate resources accordingly. Here we define the duration of the  
440 epidemic to be the time until the number of recorded cases reaches fewer than 1000 per week (orders of magnitude  
441 smaller than the peak of the epidemic). The duration of the next epidemic would decrease the further into the  
442 future in occurred, and is inversely correlated to the number of cases (Figure S6 (d)). This is because if there  
443 was a greater proportion of immunologically naive individuals in the population, the basic reproduction number  
444 would be larger and hence the virus would spread more quickly leading to a shorter epidemic duration.

445 The maximum weekly number of recorded cases (i.e. the peak of the epidemic) and the time at which this peak  
446 occurs are important to public health officials with regards to determining the maximum number of resources  
447 required to help treat patients, and when these resources would be needed. There is a direct correlation between  
448 the total number of recorded cases and the peak number of weekly recorded cases, as well as the duration of the  
449 epidemic and the time of the peak number of cases (Figure S6 (e) and (f)).




Figure S6: (a)-(b): The partially immune fraction of the 2-group model and the basic reproduction numbers of the 1-group and 2-group models if a second epidemic were to occur at a given time after the 2009 epidemic. (c)-(f): The total number number of (recorded) cases, the duration of the epidemic, the maximum number of weekly recorded cases, and the time at which this maximum occurs, if a second epidemic were to occur at a given time after the 2009 epidemic, as calculated by the 1-group and 2-group models. Quantities calculated using the mean parameter values estimated by fitting models to the 2009 H1N1 epidemic in Japan.

## 450 S.9 Forecasting an Epidemic in Real-Time with Prior Information using Different 451 Prior Parameter Distributions

452 We show real-time forecasts of an outbreak occurring 25 years after the 2009 epidemic (using prior information  
453 from the 2009 epidemic), if variances five times larger (Figure S7) or five times smaller (Figure S8) of both  $\beta$  and  
454  $N$  are used, compared to forecasts made in Figure 6. Variances remain fixed in each figure.




Figure S7: Forecasts obtained from the 1-group and 2-group models of a future epidemic occurring 25 years after the 2009 epidemic in real-time using information from previous the 2009 epidemic as in Figure 6, but with variances of the gamma distributions of  $\beta$  and  $N$  five times larger (details in Supplementary Information S.6).




Figure S8: Forecasts obtained from the 1-group and 2-group models of a future epidemic occurring 25 years after the 2009 epidemic in real-time using information from previous the 2009 epidemic as in Figure 6, but with variances of the gamma distributions of  $\beta$  and  $N$  five times smaller (details in Supplementary Information S.6).

## References

- 455  
456 Anderson, R. M. and May, R. M. *Infectious Diseases of Humans: Dynamics and Control*. Oxford University  
457 Press, 1991.
- 458 Andreasen, V., Lin, J., and Levin, S. A. The dynamics of cocirculating influenza strains conferring partial  
459 cross-immunity. *J. Math. Biol.*, 35(7):825–842, 1997. <https://doi.org/10.1007/s002850050079>.
- 460 Backer, J., Wallinga, J., Meijer, A., Donker, G., Van der Hoek, W., and Van Boven, M. The impact of influenza  
461 vaccination on infection, hospitalisation and mortality in the Netherlands between 2003 and 2015. *Epidemics*,  
462 26:77–85, 2019. <https://doi.org/10.1016/j.epidem.2018.10.001>.
- 463 Baguelin, M., Flasche, S., Camacho, A., Demiris, N., Miller, E., and Edmunds, W. J. Assessing optimal target  
464 populations for influenza vaccination programmes: an evidence synthesis and modelling study. *PLoS Med.*, 10  
465 (10):e1001527, 2013. <https://doi.org/10.1371/journal.pmed.1001527>.
- 466 Bandaranayake, D., Huang, Q. S., Bissielo, A., Wood, T., Mackereth, G., Baker, M. G., Beasley, R., Reid, S.,  
467 Roberts, S., and and, V. H. Risk factors and immunity in a nationally representative population following  
468 the 2009 influenza A(H1N1) pandemic. *PLoS One*, 5(10):e13211, 2010. <https://doi.org/10.1371/journal.pone.0013211>.
- 470 Bettencourt, L. M. and Ribeiro, R. M. Real time bayesian estimation of the epidemic potential of emerging  
471 infectious diseases. *PLoS One*, 3(5):e2185, 2008. <https://doi.org/10.1371/journal.pone.0002185>.
- 472 Biggerstaff, M., Cauchemez, S., Reed, C., Gambhir, M., and Finelli, L. Estimates of the reproduction number  
473 for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC Infect. Dis.*, 14(1),  
474 2014. <https://doi.org/10.1186/1471-2334-14-480>.
- 475 Biggerstaff, M., , Alper, D., Dredze, M., Fox, S., Fung, I. C.-H., Hickmann, K. S., Lewis, B., Rosenfeld, R.,  
476 Shaman, J., Tsou, M.-H., Velardi, P., Vespignani, A., and Finelli, L. Results from the centers for disease  
477 control and prevention’s predict the 2013–2014 influenza season challenge. *BMC Infect. Dis.*, 16(1), 2016.  
478 <https://doi.org/10.1186/s12879-016-1669-x>.
- 479 Bouvier, N. M. and Palese, P. The biology of influenza viruses. *Vaccine*, 26:D49–D53, 2008. <https://doi.org/10.1016/j.vaccine.2008.07.039>.
- 481 Chen, S.-C. and Liao, C.-M. Modelling control measures to reduce the impact of pandemic influenza among  
482 schoolchildren. *Epidemiol. Infect.*, 136(8):1035–1045, 2008. <https://doi.org/10.1017/S0950268807009284>.
- 483 Chowell, G., Nishiura, H., and Bettencourt, L. M. Comparative estimation of the reproduction number for  
484 pandemic influenza from daily case notification data. *J. R. Soc. Interface*, 4(12):155–166, 2006. <https://doi.org/10.1098/rsif.2006.0161>.
- 486 Chowell, G., Viboud, C., Wang, X., Bertozzi, S. M., and Miller, M. A. Adaptive vaccination strategies to  
487 mitigate pandemic influenza: Mexico as a case study. *PLoS One*, 4(12):e8164, 2009. <https://doi.org/10.1371/journal.pone.0008164>.
- 489 Christman, M. C., Kedwaii, A., Xu, J., Donis, R. O., and Lu, G. Pandemic (H1N1) 2009 virus revisited: an  
490 evolutionary retrospective. *Infect. Genet. Evol.*, 11(5):803–811, 2011. <https://doi.org/10.1016/j.meegid.2011.02.021>.
- 492 Cintrón-Arias, A., Castillo-Chávez, C., Bettencourt, L. M., Lloyd, A. L., and Banks, H. The estimation of the  
493 effective reproductive number from disease outbreak data. *Math. Biosci. Eng.*, 6(2):261–282, 2009. <https://doi.org/10.3934/mbe.2009.6.261>.
- 494

- 495 Dushoff, J., Plotkin, J. B., Viboud, C., Simonsen, L., Miller, M., Loeb, M., and David, J. Vaccinating to protect a  
496 vulnerable subpopulation. *PLoS Med.*, 4(5):e174, 2007. <https://doi.org/10.1371/journal.pmed.0040174>.
- 497 Ferguson, N., Laydon, D., Nedjati Gilani, G., Imai, N., Ainslie, K., Baguelin, M., Bhatia, S., Boonyasiri, A.,  
498 Cucunuba Perez, Z., Cuomo-Dannenburg, G., Dighe, A., Dorigatti, I., Fu, H., Gaythorpe, K., Green, W.,  
499 Hamlet, A., Hinsley, W., Okell, L., Van Elsland, S., Thompson, H., Verity, R., Volz, E., Wang, H., Wang, Y.,  
500 Walker, P., Winskill, P., Whittaker, C., Donnelly, C., Riley, S., and Ghani, A. Impact of non-pharmaceutical  
501 interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. 2020. <https://doi.org/10.25561/77482>.
- 503 Ferguson, N. M., Cummings, D. A., Fraser, C., Cajka, J. C., Cooley, P. C., and Burke, D. S. Strategies for  
504 mitigating an influenza pandemic. *Nature*, 442(7101):448, 2006. <https://doi.org/10.1038/nature04795>.
- 505 Fielding, J. E., Kelly, H. A., Mercer, G. N., and Glass, K. Systematic review of influenza A(H1N1)pdm09 virus  
506 shedding: duration is affected by severity, but not age. *Influenza Other Respir. Viruses*, 8(2):142–150, 2013.  
507 <https://doi.org/10.1111/irv.12216>.
- 508 Fraser, C., Donnelly, C. A., Cauchemez, S., Hanage, W. P., Van Kerkhove, M. D., Hollingsworth, T. D., Griffin,  
509 J., Baggaley, R. F., Jenkins, H. E., Lyons, E. J., et al. Pandemic potential of a strain of influenza A (H1N1):  
510 early findings. *Science*, 324(5934):1557–1561, 2009. <https://doi.org/10.1126/science.1176062>.
- 511 Funk, S., Camacho, A., Kucharski, A. J., Lowe, R., Eggo, R. M., and Edmunds, W. J. Assessing the performance  
512 of real-time epidemic forecasts: A case study of Ebola in the Western Area region of Sierra Leone, 2014–15.  
513 *PLoS Comput. Biol.*, 15(2):e1006785, 2019. <https://doi.org/10.1371/journal.pcbi.1006785>.
- 514 Gani, R., Hughes, H., Fleming, D., Griffin, T., Medlock, J., and Leach, S. Potential impact of antiviral drug  
515 use during influenza pandemic. *Emerg. Infect. Dis.*, 11(9):1355, 2005. <https://doi.org/10.3201/eid1109.041344>.
- 517 Gart, J. J. The mathematical analysis of an epidemic with two kinds of susceptibles. *Biometrics*, 24(3):557,  
518 1968. <https://doi.org/10.2307/2528318>.
- 519 Gibbons, C. L., Mangen, M.-J. J., Plass, D., Havelaar, A. H., Brooke, R. J., Kramarz, P., Peterson, K. L.,  
520 Stuurman, A. L., Cassini, A., Fèvre, E. M., et al. Measuring underreporting and under-ascertainment in  
521 infectious disease datasets: a comparison of methods. *BMC Public Health*, 14(1):147, 2014. <https://doi.org/10.1186/1471-2458-14-147>.
- 523 Glasser, J., Taneri, D., Feng, Z., Chuang, J.-H., Tüll, P., Thompson, W., McCauley, M. M., and Alexander, J.  
524 Evaluation of targeted influenza vaccination strategies via population modeling. *PLoS One*, 5(9):e12777, 2010.  
525 <https://doi.org/10.1371/journal.pone.0012777>.
- 526 Gostic, K. M., Ambrose, M., Worobey, M., and Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9  
527 influenza via childhood hemagglutinin imprinting. *Science*, 354(6313):722–726, 2016. <https://doi.org/10.1126/science.aag1322>.
- 529 Gostic, K. M., Bridge, R., Brady, S., Viboud, C., Worobey, M., and Lloyd-Smith, J. O. Childhood immune  
530 imprinting to influenza a shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. *PLoS*  
531 *Pathog.*, 15(12), 2019. <https://doi.org/10.1371/journal.ppat.1008109>.
- 532 Hall, I. M., Gani, R., Hughes, H. E., and Leach, S. Real-time epidemic forecasting for pandemic influenza.  
533 *Epidemiol. Infect.*, 135(3):372–385, 2007. <https://doi.org/10.1017/s0950268806007084>.
- 534 Hancock, K., Veguilla, V., Lu, X., Zhong, W., Butler, E. N., Sun, H., Liu, F., Dong, L., DeVos, J. R., Gargiullo,  
535 P. M., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.*,  
536 361(20):1945–1952, 2009. <https://doi.org/10.1056/NEJMoa0906453>.

- 537 Hardelid, P., Andrews, N., Hoschler, K., Stanford, E., Baguelin, M., Waight, P., Zambon, M., and Miller, E.  
538 Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1  
539 2009. *Health Technol. Assess.*, 14(55):115–92, 2010. <https://doi.org/10.3310/hta14550-03>.
- 540 Hastings, W. K. Monte Carlo sampling methods using Markov chains and their applications. *Biometrika*, 57(1):  
541 97–109, 1970. <https://doi.org/10.1093/biomet/57.1.97>.
- 542 Hill, E. M., Petrou, S., de Lusignan, S., Yonova, I., and Keeling, M. J. Seasonal influenza: Modelling approaches  
543 to capture immunity propagation. *PLoS Comput. Biol.*, 15(10):1–26, 2019. <https://doi.org/10.1371/journal.pcbi.1007096>.
- 544
- 545 Johnson, N. P. and Mueller, J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza  
546 pandemic. *Bull. Hist. Med.*, 76(1):105–115, 2002. <https://doi.org/10.1353/bhm.2002.0022>.
- 547 Kamigaki, T. and Oshitani, H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1)  
548 2009 in Japan. *PLoS Curr.*, 1:RRN1139, December 2009. <https://doi.org/10.1371/currents.rrn1139>.
- 549 Kelly, H., Peck, H. A., Laurie, K. L., Wu, P., Nishiura, H., and Cowling, B. J. The age-specific cumulative  
550 incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination.  
551 *PLoS One*, 6(8):e21828, 2011. <https://doi.org/10.1371/journal.pone.0021828>.
- 552 Kilbourne, E. D. Influenza pandemics of the 20th century. *Emerg. Infect. Dis.*, 12(1):9–14, 2006. <https://doi.org/10.3201/eid1201.051254>.
- 553
- 554 Kim, H., Webster, R. G., and Webby, R. J. Influenza virus: dealing with a drifting and shifting pathogen. *Viral*  
555 *Immunol.*, 31(2):174–183, 2018. <https://doi.org/10.1089/vim.2017.0141>.
- 556 Klepac, P., Kissler, S., and Gog, J. Contagion! the BBC Four Pandemic—the model behind the documentary.  
557 *Epidemics*, 24:49–59, 2018. <https://doi.org/10.1016/j.epidem.2018.03.003>.
- 558 Kucharski, A. J., Russell, T. W., Diamond, C., Liu, Y., Edmunds, J., Funk, S., Eggo, R. M., Sun, F., Jit, M.,  
559 Munday, J. D., Davies, N., Gimma, A., van Zandvoort, K., Gibbs, H., Hellewell, J., Jarvis, C. I., Clifford,  
560 S., Quilty, B. J., Bosse, N. I., Abbott, S., Klepac, P., and Flasche, S. Early dynamics of transmission and  
561 control of COVID-19: a mathematical modelling study. *Lancet Infect. Dis.*, 20(5):553–558, 2020. [https://doi.org/10.1016/s1473-3099\(20\)30144-4](https://doi.org/10.1016/s1473-3099(20)30144-4).
- 562
- 563 Longini, I. M., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings, D. A., and Halloran, M. E.  
564 Containing pandemic influenza at the source. *Science*, 309(5737):1083–1087, 2005. <https://doi.org/10.1126/science.1115717>.
- 565
- 566 Longini, J., Ira M., Halloran, M. E., Nizam, A., and Yang, Y. Containing pandemic influenza with antiviral  
567 agents. *Am. J. Epidemiol.*, 159(7):623–633, 2004. <https://doi.org/10.1093/aje/kwh092>.
- 568 Martcheva, M. and Pilyugin, S. S. An epidemic model structured by host immunity. *J. Biol. Syst.*, 14(02):  
569 185–203, 2006. <https://doi.org/10.1142/s0218339006001787>.
- 570 Medlock, J. and Galvani, A. P. Optimizing influenza vaccine distribution. *Science*, 325(5948):1705–1708, 2009.  
571 <https://doi.org/10.1126/science.1175570>.
- 572 Mills, C. E., Robins, J. M., and Lipsitch, M. Transmissibility of 1918 pandemic influenza. *Nature*, 432(7019):  
573 904–906, 2004. <https://doi.org/10.1038/nature03063>.
- 574 Mizumoto, K., Yamamoto, T., and Nishiura, H. Age-dependent estimates of the epidemiological impact of  
575 pandemic influenza (H1N1-2009) in Japan. *Comput. Math. Methods Med.*, 2013:1–8, 2013. <https://doi.org/10.1155/2013/637064>.
- 576



- 577 Monto, A. S. Global burden of influenza: what we know and what we need to know. *Int. Congr. Ser.*, 1263:3–11,  
578 2004. <https://doi.org/10.1016/j.ics.2004.02.049>.
- 579 National Institute of Population and Social Security Research. All Japan: Life Table Data Series | Japanese  
580 Mortality Database | National Institute of Population and Social Security Research. <http://www.ipss.go.jp/p-toukei/JMD/00/index-en.html>, 2020. Accessed on 22/01/20.
- 582 Neumann, G. and Kawaoka, Y. Predicting the next influenza pandemics. *J. Infect. Dis.*, 219(Suppl.1):S14–S20,  
583 2019. <https://doi.org/10.1093/infdis/jiz040>.
- 584 Nishiura, H. Real-time forecasting of an epidemic using a discrete time stochastic model: a case study of pandemic  
585 influenza (H1N1-2009). *Biomed. Eng. Online*, 10(1):15, 2011. <https://doi.org/10.1186/1475-925x-10-15>.
- 586 Nishiura, H., Chowell, G., Safan, M., and Castillo-Chavez, C. Pros and cons of estimating the reproduction  
587 number from early epidemic growth rate of influenza A (H1N1) 2009. *Theor. Biol. Med. Model.*, 7(1), 2010.  
588 <https://doi.org/10.1186/1742-4682-7-1>.
- 589 Ohkusa, Y., Sugawara, T., et al. Simulation model of pandemic influenza in the whole of Japan. *Jpn. J. Infect.*  
590 *Dis.*, 62(2):98–106, 2009.
- 591 Ohkusa, Y., Sugawara, T., Taniguchi, K., and Okabe, N. Real-time estimation and prediction for pan-  
592 demic A/H1N1 (2009) in Japan. *J. Infect. Chemother.*, 17(4):468–472, 2011. <https://doi.org/10.1007/s10156-010-0200-3>.
- 594 Pouillot, R., Lachenal, G., Pybus, O. G., Rousset, D., and Njouom, R. Variable epidemic histories of hepatitis  
595 C virus genotype 2 infection in West Africa and Cameroon. *Infect. Genet. Evol.*, 8(5):676–681, 2008. <https://doi.org/10.1016/j.meegid.2008.06.001>.
- 597 Prem, K., Liu, Y., Russell, T. W., Kucharski, A. J., Eggo, R. M., Davies, N., Jit, M., Klepac, P., Flasche, S.,  
598 Clifford, S., Pearson, C. A. B., Munday, J. D., Abbott, S., Gibbs, H., Rosello, A., Quilty, B. J., Jombart, T.,  
599 Sun, F., Diamond, C., Gimma, A., van Zandvoort, K., Funk, S., Jarvis, C. I., Edmunds, W. J., Bosse, N. I., and  
600 Hellewell, J. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in  
601 Wuhan, China: a modelling study. *Lancet Public Health*, 2020. [https://doi.org/10.1016/s2468-2667\(20\)](https://doi.org/10.1016/s2468-2667(20)30073-6)  
602 [30073-6](https://doi.org/10.1016/s2468-2667(20)30073-6).
- 603 Rajaram, S., Wiecek, W., Lawson, R., Blak, B. T., Zhao, Y., Hackett, J., Brody, R., Patel, V., and Amzal,  
604 B. Impact of increased influenza vaccination in 2–3-year-old children on disease burden within the general  
605 population: A Bayesian model-based approach. *PLoS One*, 12(12):e0186739, 2017. [https://doi.org/10.](https://doi.org/10.1371/journal.pone.0186739)  
606 [1371/journal.pone.0186739](https://doi.org/10.1371/journal.pone.0186739).
- 607 Reichert, T., Chowell, G., and McCullers, J. A. The age distribution of mortality due to influenza: pandemic  
608 and peri-pandemic. *BMC Med.*, 10(1):162, 2012. <https://doi.org/10.1186/1741-7015-10-162>.
- 609 Reluga, T. C., Medlock, J., and Perelson, A. S. Backward bifurcations and multiple equilibria in epidemic models  
610 with structured immunity. *J. Theor. Biol.*, 252(1):155–165, 2008. [https://doi.org/10.1016/j.jtbi.2008.](https://doi.org/10.1016/j.jtbi.2008.01.014)  
611 [01.014](https://doi.org/10.1016/j.jtbi.2008.01.014).
- 612 Taubenberger, J. K. and Morens, D. M. 1918 influenza: the mother of all pandemics. *Emerg. Infect. Dis.*, 12(1):  
613 15–22, 2006. <https://doi.org/10.3201/eid1209.05-0979>.
- 614 Thompson, R. N., Thompson, C. P., Peleman, O., Gupta, S., and Obolski, U. Increased frequency of travel in  
615 the presence of cross-immunity may act to decrease the chance of a global pandemic. *Philos. Trans. R. Soc.*  
616 *B*, 374(1775):20180274, 2019. <https://doi.org/10.1098/rstb.2018.0274>.

- 617 Thompson, R. N. Novel coronavirus outbreak in Wuhan, China, 2020: Intense surveillance is vital for pre-  
618 venting sustained transmission in new locations. *J. Clin. Med.*, 9(2):498, 2020. [https://doi.org/10.3390/  
619 jcm9020498](https://doi.org/10.3390/jcm9020498).
- 620 Thompson, R. N. and Brooks-Pollock, E. Detection, forecasting and control of infectious disease epidemics:  
621 modelling outbreaks in humans, animals and plants. *Philos. Trans. R. Soc. B*, 374(1775):20190038, 2019.  
622 <https://doi.org/10.1098/rstb.2019.0038>.
- 623 Tizzoni, M., Bajardi, P., Poletto, C., Ramasco, J. J., Balcan, D., Gonçalves, B., Perra, N., Colizza, V., and  
624 Vespignani, A. Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm.  
625 *BMC Med.*, 10(1), 2012. <https://doi.org/10.1186/1741-7015-10-165>.
- 626 Trifonov, V., Khiabani, H., and Rabadan, R. Geographic dependence, surveillance, and origins of the 2009  
627 influenza A (H1N1) virus. *N. Engl. J. Med.*, 361(2):115–119, 2009. <https://doi.org/10.1056/nejmp0904572>.
- 628 Tuite, A. R., Greer, A. L., Whelan, M., Winter, A.-L., Lee, B., Yan, P., Wu, J., Moghadas, S., Buckeridge, D.,  
629 Pourbohloul, B., et al. Estimated epidemiologic parameters and morbidity associated with pandemic H1N1  
630 influenza. *Can. Med. Assoc. J.*, 182(2):131–136, 2009. <https://doi.org/10.1503/cmaj.091807>.
- 631 Xing, Z. and Cardona, C. J. Preexisting immunity to pandemic (H1N1) 2009. *Emerg. Infect. Dis.*, 15(11):  
632 1847–1849, 2009. <https://doi.org/10.3201/eid1511.090685>.
- 633 Xu, R., Ekiert, D. C., Krause, J. C., Hai, R., Crowe, J. E., and Wilson, I. A. Structural basis of preexisting  
634 immunity to the 2009 H1N1 pandemic influenza virus. *Science*, 328(5976):357–360, 2010. [https://doi.org/  
635 10.1126/science.1186430](https://doi.org/10.1126/science.1186430).